{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-094102","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.463579+00:00","generated_at":"2026-05-31T10:53:56.815559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tempest reports Q2 2024 financials; amezalpat shows 6-month survival benefit in liver cancer study","bullets":["Amezalpat median OS 21 months vs 15 months control (6-month improvement); HR 0.65 stable from prior 0.59.","Company plans to advance amezalpat into a registrational Phase 3 study in first-line HCC.","TPST-1495 to enter Phase 2 in Familial Adenomatous Polyposis in 2024 under NCI funding.","Q2 2024 net loss $9.6M ($0.42 per share); cash and equivalents $31.1M as of June 30, 2024.","R&D expenses $5.8M in Q2 2024 vs $4.4M in Q2 2023, increase due to CRO costs and stock compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-094102","json":"https://secwatch.observer/filing/0000950170-24-094102.json","markdown":"https://secwatch.observer/filing/0000950170-24-094102.md","text":"https://secwatch.observer/filing/0000950170-24-094102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024094102/0000950170-24-094102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024094102/tpst-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:53:56.815559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}